Evidence map›Paper›PMID 40317671›Full record

ArticleAmerican journal of medical genetics. Part A2025

Worth the Effort: Lessons for Discovery and Care From an Unusual Case of Gorlin Syndrome.

V Taliercio, J Zhao, S E Boyden, R Mao, P Bayrak-Toydemir, A Pflaum, J Palumbos, A Andrews, E E Baldwin, C Welt and 4 more

Abstract readCase Reports
In one paragraph

Article in American journal of medical genetics. Part A, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

V TaliercioDepartment of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0001-6226-3576
J ZhaoDepartment of Pathology, University of Utah, Salt Lake City, Utah, USA.ORCID https://orcid.org/0009-0001-3366-5194
S E BoydenUtah Center for Genetic Discovery, Department of Human Genetics, University of Utah, Salt Lake City, Utah, USA.
R MaoDepartment of Pathology, University of Utah, Salt Lake City, Utah, USA.
P Bayrak-ToydemirDepartment of Pathology, University of Utah, Salt Lake City, Utah, USA.
A PflaumARUP Laboratories, Salt Lake City, Utah, USA.
J PalumbosDepartment of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, Utah, USA.
A AndrewsDepartment of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, Utah, USA.
E E BaldwinDepartment of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, Utah, USA.
C WeltDivision of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Mackenzie FaitDepartment of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, Utah, USA.
Undiagnosed Diseases NetworkNational Institutes of Health Undiagnosed Diseases Network, Common Fund, Office of the Director and the National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
L D BottoDepartment of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0002-5322-7116
D ViskochilDepartment of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0001-5364-3366

Funding

CTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
$21.9M
Intermountain West Clinical Site for the Undiagnosed Disease Network (UDN) Phase 2 SupplementU01HG010217 · NHGRI · UNIVERSITY OF UTAH · PI BOTTO, LORENZO DAVIDE · 2018 to 2022
$2.8M
Intermountain West Clinical Site for the Undiagnosed Disease Network (UDN) ContinuationU01NS134351 · NINDS · UNIVERSITY OF UTAH · PI BOTTO, LORENZO DAVIDE · 2023 to 2023
$616k
From genomics to natural language processing: A protected environment for research computing in the health scienceS10OD021644 · OD · UNIVERSITY OF UTAH · PI CHEATHAM, THOMAS E. · 2017 to 2017
$494k
NCATS NIH HHS UM1 TR004409NHGRI NIH HHS U01 HG010217NIH HHS S10 OD021644NINDS NIH HHS U01 NS134351Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke of the National Institutes of Health under Award Number U01HG010217The research reported in this publication was also supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UM1TR004409
6 · The paper itself

Abstract

Gorlin-Goltz Syndrome (GGS) is a rare autosomal dominant genetic disorder encompassing a diverse range of clinical manifestations, including congenital anomalies and predisposition to cancer. Pathogenic variants in PTCH1 and SUFU account for up to 79% and 6% of cases, respectively. Currently, an estimated 15%-27% of individuals with a clinical diagnosis of GGS do not have a pathogenic variant identified in either gene. We report on a 17-year-old female referred to the Undiagnosed Disease Network with a clinical diagnosis of GGS that manifested as both classic and unusual findings, including isolated hypogonadotropic hypogonadism and anosmia (Kallmann syndrome), orofacial cleft, and abnormal semicircular canals (SCC). Prior genetic testing, including a targeted gene panel, genomic microarray, exome sequencing, and genome sequencing, was non-diagnostic, although these studies identified a variant of uncertain significance in CHD7, which may have contributed to elements of the phenotype (e.g., abnormal SCC). Reanalysis of genome sequencing data using research analytic methods, together with karyotyping, FISH, and Sanger sequencing, identified a novel de novo paracentric inversion that truncated PTCH1. These findings underscore the value of in-depth phenotype-guided genomic analysis, including chromosomal structural variants, as well as the occurrence of possible dual genetic diagnoses in the same individuals. Moreover, the definitive diagnosis provided the patient and family with a firmer basis for management and counseling.

Indexed as

Basal Cell Nevus SyndromeDNA HelicasesPatched-1 ReceptorAdolescentDNA-Binding ProteinsFemaleGenetic TestingHumansPhenotypeCHD7 protein, humanDNA-Binding ProteinsDNA HelicasesPatched-1 ReceptorPTCH1 protein, humanCHARGE syndromegeneticsgenodermatosesGorlin‐Goltz syndrome

Identifiers

PMID40317671
PMCPMC12339197

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.